← Back to Search

Small Molecule Inhibitor

YL-15293 for Solid Tumors

Phase 1 & 2

Waitlist Available

Research Sponsored by Shanghai YingLi Pharmaceutical Co. Ltd.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up throughout the study for approximately 2 years

Awards & highlights

Study Summary

This trial is testing a new drug, YY-15293, to see if it is safe and effective in treating patients with advanced solid tumors (cancer that has spread) with a KRAS G12C mutation.

Eligible Conditions

Advanced Solid Tumors

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ throughout the study for approximately 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~throughout the study for approximately 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout the study for approximately 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The overall response rate (ORR)

Secondary outcome measures

Disease control rate, DCR

Overall survival, OS

Progression free survival, PFS

Trial Design

1Treatment groups

Experimental Treatment

Group I: YL-15293Experimental Treatment1 Intervention

After a screening period of approximately 28 days, eligible patients will receive oral YL-15293 once daily until documented disease progression, unacceptable AEs, intercurrent illness prevents further administrations of study treatment, investigator's decision to withdraw the patient, the patient withdraws consent, pregnancy of the patient, or for administrative reasons. Following the end of treatment, patients will continue to be followed for safety for 30 days. Patients who permanently discontinue study treatment for reasons other than disease progression will have post-treatment follow-up for disease assessment until start of new anticancer treatment, patient withdraws consent, is lost to follow-up, death, or until the Sponsor stops the study, whichever comes first.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Shanghai YingLi Pharmaceutical Co. Ltd.Lead Sponsor

20 Previous Clinical Trials

1,571 Total Patients Enrolled

Yingli Pharma US, IncUNKNOWN

1 Previous Clinical Trials

54 Total Patients Enrolled

Media Library

YL-15293 (Small Molecule Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05119933 — Phase 1 & 2

Solid Tumors Research Study Groups: YL-15293

Solid Tumors Clinical Trial 2023: YL-15293 Highlights & Side Effects. Trial Name: NCT05119933 — Phase 1 & 2

YL-15293 (Small Molecule Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05119933 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still openings for enrolment in this trial?

"Confirmed. Clinicaltrials.gov reports that this medical experiment was initially announced on November 9th 2021 and has been most recently updated on the 11th of the same month, indicating it is actively seeking participants."

Answered by AI

What is the current intake quota for this clinical trial?

"The sponsor, Shanghai YingLi Pharmaceutical Co. Ltd., must enroll 55 qualified participants across multiple sites; including Oncology Consultants in Houston and Innovative Clinical Research Institute in Whittier."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

2021. "A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05119933.